SUPPLEMENT
Q1 2021 — Sales of Key Products/Franchises
Q1 2021PDF · 7 pages123 KB
REPORTED SALES vs. PRIOR PERIOD ($MM) FIRST QUARTER 2021 2020 Reported Operational (1) Currency CONSUMER HEALTH SEGMENT (2) OTC US 599 $ 689 -13.0% -13.0% - Intl 575 659 -12.8% -16.6% 3.8% WW 1,175 1,348 -12.9% -14.8% 1.9% SKIN HEALTH / BEAUTY US 634 659 -3.9% -3.9% - Intl 529 458 15.7% 12.3% 3.4% WW 1,163 1,117 4.1% 2.8% 1.3% ORAL CARE US 163 176 -7.2% -7.2% - Intl 254 219 16.0% 13.9% 2.1% WW 417 395 5.7% 4.5% 1.2% BABY CARE US 96 92 4.2% 4.2% - Intl 293 269 8.9% 11.3% -2.4% WW 389 361 7.7% 9.5% -1.8% WOMEN'S HEALTH US 3 4 -25.8% -25.8% - Intl 219 228 -3.9% -2.2% -1.7% WW 222 232 -4.3% -2.6% -1.7% WOUND CARE / OTHER US 115 119 -3.0% -3.0% - Intl 61 52 17.6% 14.2% 3.4% WW 177 171 3.3% 2.2% 1.1% TOTAL CONSUMER HEALTH US 1,611 1,740 -7.4% -7.4% - Intl 1,932 1,885 2.5% 0.5% 2.0% WW 3,543 $ 3,625 -2.3% -3.3% 1.0% See footnotes at end of schedule % Change -- 1 of 7 -- REPORTED SALES vs. PRIOR PERIOD ($MM) FIRST QUARTER PHARMACEUTICAL SEGMENT (2,3) 2021 2020 Reported Operational (1) Currency IMMUNOLOGY US 2,413 $ 2,410 0.1% 0.1% - Intl 1,501 1,228 22.3% 15.9% 6.4% WW 3,914 3,638 7.6% 5.5% 2.1% REMICADE US 489 625 -21.7% -21.7% - US Exports (4) 57 110 -48.4% -48.4% - Intl 232 256 -9.4% -12.1% 2.7% WW 777 990 -21.5% -22.2% 0.7% SIMPONI / SIMPONI ARIA US 255 272 -5.9% -5.9% - Intl 307 258 18.9% 13.8% 5.1% WW 562 529 6.2% 3.7% 2.5% STELARA US 1,331 1,217 9.4% 9.4% - Intl 817 603 35.6% 27.6% 8.0% WW 2,148 1,819 18.1% 15.4% 2.7% TREMFYA US 274 187 46.3% 46.3% - Intl 143 109 32.0% 23.1% 8.9% WW 418 296 41.0% 37.8% 3.2% OTHER IMMUNOLOGY US 7 - * * - Intl 2 3 -38.4% -36.3% -2.1% WW 8 3 * * * INFECTIOUS DISEASES US 512 436 17.4% 17.4% - Intl 494 483 2.3% -2.2% 4.5% WW 1,007 920 9.5% 7.1% 2.4% COVID-19 VACCINE US 100 - * * - Intl - - - - - WW 100 - * * - EDURANT / rilpivirine US 10 12 -12.3% -12.3% - Intl 233 212 9.8% 0.9% 8.9% WW 243 224 8.6% 0.2% 8.4% PREZISTA / PREZCOBIX / REZOLSTA / SYMTUZA US 380 396 -3.8% -3.8% - Intl 166 184 -9.9% -10.4% 0.5% WW 546 579 -5.8% -5.9% 0.1% OTHER INFECTIOUS DISEASES US 21 29 -27.0% -27.0% - Intl 96 87 9.7% 7.4% 2.3% WW 117 116 0.6% -1.2% 1.8% % Change -- 2 of 7 -- REPORTED SALES vs. PRIOR PERIOD ($MM) FIRST QUARTER 2021 2020 Reported Operational (1) Currency NEUROSCIENCE US 771 748 3.2% 3.2% - Intl 949 910 4.3% 0.4% 3.9% WW 1,721 1,658 3.8% 1.6% 2.2% CONCERTA / Methylphenidate US 47 52 -9.6% -9.6% - Intl 123 118 4.5% -0.4% 4.9% WW 171 171 0.2% -3.2% 3.4% INVEGA SUSTENNA / XEPLION / INVEGA TRINZA / TREVICTA US 589 544 8.3% 8.3% - Intl 376 339 11.0% 4.5% 6.5% WW 965 883 9.4% 6.9% 2.5% RISPERDAL CONSTA US 67 76 -11.8% -11.8% - Intl 89 94 -4.8% -8.8% 4.0% WW 157 170 -7.9% -10.1% 2.2% OTHER NEUROSCIENCE US 67 75 -9.8% -9.8% - Intl 361 360 0.2% -0.9% 1.1% WW 428 435 -1.5% -2.5% 1.0% ONCOLOGY US 1,377 1,175 17.2% 17.2% - Intl 2,193 1,839 19.3% 12.9% 6.4% WW 3,570 3,013 18.5% 14.6% 3.9% DARZALEX US 691 463 49.2% 49.2% - Intl 674 474 42.2% 35.3% 6.9% WW 1,365 937 45.6% 42.2% 3.4% ERLEADA US 171 119 44.0% 44.0% - Intl 90 24 * * * WW 261 143 82.8% 79.7% 3.1% IMBRUVICA US 444 432 2.8% 2.8% - Intl 680 599 13.5% 7.6% 5.9% WW 1,125 1,031 9.0% 5.6% 3.4% ZYTIGA / abiraterone acetate US 50 139 -64.2% -64.2% - Intl 588 552 6.6% 0.0% 6.6% WW 638 690 -7.6% -12.9% 5.3% OTHER ONCOLOGY (5) US 21 22 -5.1% -5.1% - Intl 161 190 -15.3% -19.3% 4.0% WW 182 212 -14.2% -17.9% 3.7% % Change -- 3 of 7 -- REPORTED SALES vs. PRIOR PERIOD ($MM) FIRST QUARTER 2021 2020 Reported Operational (1) Currency PULMONARY HYPERTENSION US 573 486 18.0% 18.0% - Intl 288 260 10.8% 5.6% 5.2% WW 861 745 15.5% 13.7% 1.8% OPSUMIT US 272 229 18.5% 18.5% - Intl 179 160 11.5% 6.3% 5.2% WW 450 389 15.6% 13.5% 2.1% UPTRAVI US 259 212 21.9% 21.9% - Intl 46 38 23.0% 15.7% 7.3% WW 305 250 22.0% 20.9% 1.1% OTHER PULMONARY HYPERTENSION US 42 44 -3.5% -3.5% - Intl 63 62 1.4% -2.1% 3.5% WW 105 106 -0.6% -2.7% 2.1% CARDIOVASCULAR / METABOLISM / OTHER US 799 806 -0.9% -0.9% - Intl 328 354 -7.2% -11.3% 4.1% WW 1,127 1,160 -2.8% -4.1% 1.3% XARELTO US 589 527 11.7% 11.7% - Intl - - - - - WW 589 527 11.7% 11.7% - INVOKANA / INVOKAMET US 87 117 -26.1% -26.1% - Intl 63 58 9.2% 4.2% 5.0% WW 150 175 -14.4% -16.1% 1.7% PROCRIT / EPREX US 62 76 -18.3% -18.3% - Intl 64 79 -18.1% -22.2% 4.1% WW 127 155 -18.2% -20.3% 2.1% OTHER US 60 85 -28.8% -28.8% - Intl 201 217 -7.7% -11.5% 3.8% WW 261 302 -13.6% -16.4% 2.8% TOTAL PHARMACEUTICAL US 6,446 6,061 6.4% 6.4% - Intl 5,753 5,073 13.4% 7.9% 5.5% WW 12,199 $ 11,134 9.6% 7.1% 2.5% See footnotes at end of schedule % Change -- 4 of 7 -- REPORTED SALES vs. PRIOR PERIOD ($MM) FIRST QUARTER MEDICAL DEVICES SEGMENT (2) 2021 2020 Reported Operational (1) Currency INTERVENTIONAL SOLUTIONS US 434 $ 365 19.0% 19.0% - Intl 514 362 42.0% 34.0% 8.0% WW 949 727 30.4% 26.4% 4.0% ORTHOPAEDICS US 1,249 1,250 -0.1% -0.1% - Intl 864 788 9.7% 3.1% 6.6% WW 2,113 2,038 3.7% 1.2% 2.5% HIPS US 210 206 2.4% 2.4% - Intl 146 132 11.2% 4.5% 6.7% WW 357 337 5.8% 3.2% 2.6% KNEES US 185 214 -13.5% -13.5% - Intl 132 130 2.0% -4.1% 6.1% WW 317 343 -7.6% -9.9% 2.3% TRAUMA US 450 407 10.7% 10.7% - Intl 282 247 14.4% 7.7% 6.7% WW 733 654 12.1% 9.5% 2.6% SPINE, SPORTS & OTHER US 403 423 -4.8% -4.8% - Intl 303 280 8.4% 1.7% 6.7% WW 706 703 0.4% -2.2% 2.6% % Change -- 5 of 7 -- REPORTED SALES vs. PRIOR PERIOD ($MM) FIRST QUARTER 2021 2020 Reported Operational (1) Currency SURGERY US 898 844 6.5% 6.5% - Intl 1,474 1,257 17.3% 11.7% 5.6% WW 2,372 2,100 12.9% 9.6% 3.3% ADVANCED US 405 381 6.5% 6.5% - Intl 713 567 25.7% 19.5% 6.2% WW 1,118 948 18.0% 14.3% 3.7% GENERAL US 493 463 6.5% 6.5% - Intl 761 690 10.3% 5.3% 5.0% WW 1,254 1,153 8.8% 5.8% 3.0% VISION US 472 439 7.4% 7.4% - Intl 673 628 7.3% 3.9% 3.4% WW 1,145 1,067 7.3% 5.4% 1.9% CONTACT LENSES / OTHER US 371 346 7.2% 7.2% - Intl 486 467 4.0% 0.9% 3.1% WW 857 814 5.3% 3.5% 1.8% SURGICAL US 101 93 8.2% 8.2% - Intl 187 160 17.0% 12.9% 4.1% WW 288 253 13.7% 11.2% 2.5% TOTAL MEDICAL DEVICES US 3,054 2,898 5.4% 5.4% - Intl 3,525 3,034 16.2% 10.5% 5.7% WW 6,579 $ 5,932 10.9% 8.0% 2.9% * Percentage greater than 100% or not meaningful (1) Operational growth excludes the effect of translational currency (2) Unaudited (3) Certain prior year amounts have been reclassified to conform to current year product disclosures (4) Reported as U.S. sales (5) Refer to supplemental schedule Note: Columns and rows within tables may not add due to rounding. Percentages have been calculated using actual, non-rounded figures and, therefore, may not recalculate precisely. % Change -- 6 of 7 -- Full Year Q1 Q2 Q3 Q4 Full Year PHARMACEUTICAL SEGMENT(1) Oncology OTHER ONCOLOGY(2) US 70 22 20 21 20 83 Intl 1,087 190 185 181 183 738 WW 1,158 212 204 203 202 821 Note: Columns and rows within tables may not add due to rounding. (1) Unaudited (2) Other Oncology is inclusive of VELCADE, which was previously disclosed separately Supplemental Sales Information (Dollars in Millions) Prior quarter amounts have been reclassified to conform to current quarter product disclosure 2019 2020 2020 -- 7 of 7 --